New hope for advanced stomach cancer: experimental combo targets tumors after first-line failure

NCT ID NCT07361991

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital of Zhengzhou University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called IBI363, which helps the immune system attack cancer cells, combined with other drugs (bevacizumab with or without nab-paclitaxel) as a second treatment for people with advanced stomach cancer. About 50 adults aged 18-75 whose cancer worsened after initial therapy will participate. The goal is to check safety and see if the combination shrinks tumors or slows disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVAN'CE'D ADVANCED

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Contact Phone: •••-•••-•••• Email: •••••@•••••